Covidien Announces Results from 2013 Annual General Meeting
- Election of Directors
- Appointment of Independent Auditors
- An advisory vote to approve the Company's executive compensation
- Approval of the amended and restated Covidien Stock and Incentive Plan
- Authorization of the Company and/or any subsidiary to make market purchases of Company shares
- Authorization of the reissue price range of treasury shares
- Amendment of the Company's Articles of Association to expand the authority to execute instruments of transfer, and
- An advisory vote on the creation of distributable reserves for Mallinckrodt plc.
At the meeting, shareholders elected all 10 nominees, each of whom currently serves on Covidien's Board of Directors. They are: José E. Almeida, Joy A. Amundson, Craig Arnold, Robert H. Brust, John M. Connors, Jr., Christopher J. Coughlin, Randall J. Hogan, III, Martin D. Madaus, Dennis H. Reilley and Joseph A. Zaccagnino. In addition, the Directors elected Mr. Reilley to be the Lead Director, replacing Timothy M. Donahue, who did not stand for reelection to the Board.
Shareholders also approved the appointment of Deloitte & Touche LLP to serve as the Company's independent auditors, and, in an advisory vote, approved the Company's executive compensation. Shareholders approved the amended and restated Covidien Stock and Incentive Plan, authorized Covidien and/or any of its subsidiaries to make market purchases of Company shares and authorized the price range at which the Company can reissue shares it holds as treasury shares. In addition, shareholders also approved an amendment to Covidien's Articles of Association to expand the authority to execute instruments of transfer and, in an advisory vote, approved the creation of distributable reserves for Mallinckrodt plc.
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.
Bruce Farmer, 508-452-4372
Coleman Lannum, CFA, 508-452-4343
Todd Carpenter, 508-452-4363
KEYWORDS: Europe Ireland
The article Covidien Announces Results from 2013 Annual General Meeting originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.